Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic
Synthego, the genome engineering company, in Feb. 17, 2022 announced it has raised $200 million of growth capital. "we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients," said Paul Dabrowski, co-founder and CEO of Synthego.
CRISPR has become a powerful discovery tool, and the field is now at an inflection point and its clinical applications to treat a myriad of serious diseases, including cancer and genetic disorders, is within reach.
Synthego will use the proceeds from the Series E financing to accelerate the creation of a cell and gene therapy discovery and development ecosystem to help researchers scale and simplify the translation of new discoveries into novel therapeutics for serious diseases. Specifically, Synthego plans to expand both the capacity and capabilities of its Halo and Eclipse Platforms for research and discovery applications, continuing to drive broad accessibility of genome engineering tools and genome engineered cells. Synthego will also invest in next-generation technologies such as CRISPROff, a light-based system for specific and precise CRISPR editing, and increase its Good Manufacturing Practice (GMP) manufacturing capabilities to support its customers' clinical and therapeutic programs.
The development of next-generation CRISPR-based cellular and genetic medicines requires the ability to rapidly discover new biology, deploy advanced bioinformatics, optimize and perform precision genome editing, and seamlessly translate from research into clinical settings.
Synthego brought together more than 12,000 CRISPR researchers at the largest annual global CRISPR conference, leveraged its Eclipse Platform to rapidly accelerate critical programs in COVID-19 research and neurodegenerative diseases, and is enabling the rapid translation of CRISPR-based cell and gene therapies into the clinic through the ISO 9001 certification of its GMP manufacturing capabilities.
For more information on Synthego, please visit the company's website at www.Synthego.com.
Reference :
https://www.prnewswire.com/news-releases/synthego-raises-200-million-to-accelerate-the-field-of-crispr-based-medicines-from-early-phase-research-to-the-clinic-301484417.html.
ارسال به دوستان